Cue Biopharma Q1 net loss $5.2M; appoints new CEO, $30M private placement, CUE-221 license

Cue Biopharma, Inc.

2026-Q1 EPS reported -$1.08 revenue$5,686,000

Net loss $5.2M ($1.08 EPS) vs $12.3M loss in Q1 2025; revenue $5.7M from Boehringer collaboration.
Appointed Shao-Lee Lin, M.D., Ph.D., as President, CEO and Board Director.
Completed $30M private placement (pre-funded and common warrants); received $7.5M milestone from Boehringer.
Exclusive license for CUE-221 (Phase 2 anti-IgE) from Ascendant Health; IND amendment for food allergy expected H2 2026.
Cash $16.4M at Mar 31, 2026; subsequent $30M private placement extends runway for clinical milestones.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.